Abstract:The finding that most GBMs recur either near or within the primary site after radiotherapy has fueled great interest in the development of radiosensitizers to enhance local control. Unfortunately, decades of clinical trials testing a wide range of novel therapeutic approaches have failed to yield any clinically viable radiosensitizers (1). However, it is well-recognized that temozolomide chemotherapy is administered concurrently with radiotherapy specifically as a radiosensitizer. Furthermore, it can be argued that many of the previous radiosensitizing strategies, for GBM and many other tumor types were not backed by firm pre-clinical evidence supporting a synergistic or additive interaction (2). Another poorly understood variable is lack of blood-brain barrier penetration as potential limitation for treatment efficacy, as until recently most clinical trials did not assess the actual drug levels in GBM tumors. Finally, despite an understanding that DNA repair status was an important variable for radiotherapy treatment responses dating back to the 1970's, the actual DNA repair pathways and proteins were only fully elucidated in the last decade. Here, we present recent progress in the use of small molecule DNA damage response inhibitors as GBM radiosensitizers. In addition, we discuss the latest progress in targeting hypoxia and oxidative stress for GBM radiosensitization. Introduction. The finding that most GBMs recur either near or within the primary site after radiotherapy has fueled great interest in the development of radiosensitizers to enhance local control. Unfortunately, decades of clinical trials testing a wide range of novel therapeutic approaches have failed to yield any clinically viable radiosensitizers (1). However, it is well-recognized that temozolomide chemotherapy is administered concurrently with radiotherapy specifically as a radiosensitizer. Furthermore, it can be argued that many of the previous radiosensitizing strategies, for GBM and many other tumor types were not backed by firm pre-clinical evidence supporting a synergistic or additive interaction (2). Another poorly understood variable is lack of blood-brain barrier penetration as potential limitation for treatment efficacy, as until recently most clinical trials did not assess the actual drug levels in GBM tumors. Finally, despite an understanding that DNA repair status was an important variable for radiotherapy treatment responses dating back to the 1970's, the actual DNA repair pathways and proteins were only fully elucidated in the last decade. Here, we present recent progress in the use of small molecule DNA damage response inhibitors as GBM radiosensitizers. In addition, we discuss the latest progress in targeting hypoxia and oxidative stress for GBM radiosensitization.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation